Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
Highly innovative and ambitious collaborative projects in translational cancer research at European and international level.
Característiques principals
The expected impact of the call is to improve the efficacy of personalized treatment of cancer patients through the development of new tools and targeted immunotherapy strategies, based on a better understanding of tumour microenvironment functions and of their impact on the disease course.

AIMS OF THE CALL:
  • Aim 1: Identification and validation of TME subclasses and their contribution to the resistance mechanisms: Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients.
  • Aim 2: Identification and validation of TME subclasses and their contribution to the resistance mechanisms: Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Marta López: mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    http://transcan.eu/opencall.html
    Informació addicional
    Aplicatiu web:https://ptoutline.eu/app/transcan2021
    Requisits
    Consortia composition (see the Call Text for complete information):
  • Each research consortium must involve a minimum of three (3) and a maximum of six (6) partners, eligible for funding, coming from different countries whose funders participate in the call.
  • The partners must be from at least three (3) different countries participating in the call. In addition, a consortium must not involve more than two (2) research groups from the same country (in such cases the minimum number of groups must be 4, coming from 3 different countries).
  • A wide inclusion of research teams from all the countries/regions participating in the call is encouraged, with a particular attention to research teams from Latvia, Slovakia and Turkey, in order to strengthen the European translational cancer research area.

    For Spanish applicants: please check the eligibility requirements of the institution and the principal investigator/team members, in pages 47-52 of the Guidelines.

    		•
    Dotació
    For Spanish participants requesting funding to ISCIII:
  • up to 150,000 € (overheads included) per partner
  • up to 200.000 € (overheads included) per coordinator

    For Spanish participants requesting funding to FCAECC:up to 150.000€ (overheads not included)
    • Durada
    3 years
    AVÍS IMPORTANT
    En cas de voler presentar-vos a la convocatòria, per favor no contacteu directament amb ISCIII/FCAECC, dirigiu-vos al Servei de Recerca (Carol Barnwell / Marta López).

    Arxius

    Arxiu
    TRANSCAN-3_Guidelines_for_applicants_JTC-2021.pdf
    TRANSCAN-3_Call text_Co-funded_JTC-2021.pdf